



(51) International Patent Classification:
A61K 38/16 (2006.01)

(21) International Application Number:
PCT/US2021/037061

(22) International Filing Date:
11 June 2021 (11.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/038,606 12 June 2020 (12.06.2020) US
63/039,225 15 June 2020 (15.06.2020) US

(71) Applicant: **PHARMAIN CORPORATION** [US/US];
11812 North Creek Parkway North, Suite 101, Bothell,
Washington 98011 (US).

(72) Inventors; and

(71) Applicants: **TACHIBANA, Hirofumi** [JP/JP]; c/o 11812
North Creek Parkway North, Suite 101, Bothell, Wash-
ington 98011 (US). **KUMAZOE, Motofumi** [JP/JP]; c/
o 11812 North Creek Parkway North, Suite 101, Bothell,
Washington 98011 (US). **TANAKA, Yasutake** [JP/JP]; c/
o 11812 North Creek Parkway North, Suite 101, Bothell,
Washington 98011 (US). **NOJIRI, Takashi** [JP/JP]; c/
o 11812 North Creek Parkway North, Suite 101, Bothell,
Washington 98011 (US). **CASTILLO, Gerardo** [US/US];
c/o 11812 North Creek Parkway North, Suite 101, Bothell,
Washington 98011 (US). **NISHIMOTO-ASHFIELD, Akiko** [US/US]; c/o 11812 North Creek Parkway North,
Suite 101, Bothell, Washington 98011 (US). **BOLOTIN, Elijah** [US/US]; c/o 11812 North Creek Parkway North,
Suite 101, Bothell, Washington 98011 (US). **YAO, Yao** [US/US]; c/o 11812 North Creek Parkway North, Suite 101,
Bothell, Washington 98011 (US).

(54) Title: C-TYPE NATRIURETIC PEPTIDES AND METHODS THEREOF IN TREATING CANCER




FIG. 20

(57) Abstract: The present disclosure relates to methods of treating a subject having abnormal vasculature by administering to the subject a therapeutically effective bolus dose of a composition including a long acting C-type natriuretic peptide (CNP), CNP derivative, long acting CNP derivative, long acting CNP receptor (NPRB) agonist, or any combination thereof. The present disclosure further relates to treating a subject in need of an increase in cytotoxic T cell and/or NK cell activity by administering to the subject a therapeutically effective bolus dose of a composition including a long acting C-type natriuretic peptide (CNP), CNP derivative, long acting CNP derivative, long acting CNP receptor (NPRB) agonist, or any combination thereof.

[Continued on next page]

(74) **Agent: ZHENG, Juan;** Christensen O'Connor Johnson
Kindness PLLC, 1201 Third Avenue, Suite 3600, Seattle,
Washington 98101 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))